11,379 Shares in Humacyte, Inc. (NASDAQ:HUMA) Purchased by ACT Wealth Management LLC

ACT Wealth Management LLC acquired a new stake in shares of Humacyte, Inc. (NASDAQ:HUMA) during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 11,379 shares of the company’s stock, valued at approximately $57,000.

Other large investors also recently bought and sold shares of the company. Private Advisor Group LLC grew its position in shares of Humacyte by 1.8% during the 3rd quarter. Private Advisor Group LLC now owns 373,110 shares of the company’s stock valued at $2,030,000 after buying an additional 6,510 shares during the last quarter. The Manufacturers Life Insurance Company grew its holdings in shares of Humacyte by 32.5% during the second quarter. The Manufacturers Life Insurance Company now owns 34,919 shares of the company’s stock valued at $168,000 after purchasing an additional 8,557 shares during the last quarter. China Universal Asset Management Co. Ltd. raised its position in shares of Humacyte by 64.1% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 22,955 shares of the company’s stock worth $125,000 after purchasing an additional 8,965 shares during the period. Brookstone Capital Management acquired a new position in Humacyte during the 4th quarter valued at approximately $56,000. Finally, XTX Topco Ltd grew its stake in Humacyte by 48.8% during the 3rd quarter. XTX Topco Ltd now owns 34,049 shares of the company’s stock worth $185,000 after buying an additional 11,172 shares during the last quarter. Institutional investors own 44.71% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have issued reports on the company. HC Wainwright reiterated a “buy” rating and issued a $15.00 target price (up from $12.00) on shares of Humacyte in a research note on Friday, December 20th. D. Boral Capital reissued a “buy” rating and set a $25.00 target price on shares of Humacyte in a research note on Tuesday. BTIG Research restated a “buy” rating and issued a $10.00 price target on shares of Humacyte in a research note on Friday, October 18th. Benchmark boosted their price objective on Humacyte from $15.00 to $17.00 and gave the stock a “buy” rating in a research report on Monday, December 23rd. Finally, Piper Sandler set a $6.00 target price on Humacyte and gave the company a “neutral” rating in a research report on Friday, October 18th. One research analyst has rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Buy” and an average target price of $13.71.

Humacyte Price Performance

NASDAQ HUMA opened at $4.56 on Wednesday. Humacyte, Inc. has a 12 month low of $2.69 and a 12 month high of $9.97. The firm has a market capitalization of $573.92 million, a PE ratio of -3.40 and a beta of 1.32. The company’s 50 day simple moving average is $4.55 and its 200 day simple moving average is $5.65.

Humacyte (NASDAQ:HUMA) last issued its quarterly earnings results on Friday, November 8th. The company reported ($0.33) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.25) by ($0.08). During the same quarter in the prior year, the business posted ($0.25) earnings per share. Sell-side analysts anticipate that Humacyte, Inc. will post -1.27 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, Director Brady W. Dougan sold 427,459 shares of Humacyte stock in a transaction that occurred on Tuesday, November 19th. The shares were sold at an average price of $4.34, for a total value of $1,855,172.06. Following the transaction, the director now owns 1,992,253 shares of the company’s stock, valued at $8,646,378.02. The trade was a 17.67 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, CEO Laura E. Niklason sold 261,369 shares of the business’s stock in a transaction that occurred on Wednesday, November 20th. The stock was sold at an average price of $4.40, for a total transaction of $1,150,023.60. Following the completion of the sale, the chief executive officer now owns 1,730,884 shares in the company, valued at $7,615,889.60. The trade was a 13.12 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 1,500,000 shares of company stock worth $6,606,799. 11.20% of the stock is owned by corporate insiders.

Humacyte Company Profile

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.